Hims & Hers Health, Inc. $HIMS Shares Acquired by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 15.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,261 shares of the company’s stock after buying an additional 3,390 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Hims & Hers Health were worth $1,259,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health during the 1st quarter worth approximately $30,000. UMB Bank n.a. increased its position in shares of Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after purchasing an additional 933 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Hims & Hers Health during the first quarter worth approximately $41,000. Larson Financial Group LLC increased its position in shares of Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Finally, Webster Bank N. A. increased its position in shares of Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after purchasing an additional 630 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HIMS shares. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. UBS Group set a $30.00 price target on Hims & Hers Health in a research report on Monday, June 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Saturday, September 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Finally, Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Hims & Hers Health presently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Stock Down 0.1%

Shares of NYSE:HIMS opened at $58.13 on Friday. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The business has a fifty day moving average of $51.03 and a two-hundred day moving average of $47.78. The stock has a market cap of $13.14 billion, a P/E ratio of 72.67, a PEG ratio of 3.93 and a beta of 2.25. Hims & Hers Health, Inc. has a 52-week low of $17.36 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s quarterly revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $58.79, for a total value of $155,029.23. Following the completion of the sale, the insider directly owned 163,767 shares in the company, valued at $9,627,861.93. This represents a 1.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 8,410 shares of the stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the transaction, the insider owned 1,418 shares of the company’s stock, valued at approximately $71,609. This represents a 85.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,622,741 shares of company stock worth $83,695,469 over the last quarter. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.